Acute Effects of BZP, TFMPP and the Combination of BZP and TFMPP in Comparison to Dexamphetamine on an Auditory Oddball Task Using Electroencephalography: a Single-dose Study

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2015 Dec 4

PMID 26630992

Citations 5

Authors

Heeseung Lee

Grace Y Wang

Louise E Curley

John J Sollers

Rob R Kydd

Ian J Kirk

Bruce R Russell

Affiliations

Soon will be listed here.

Abstract

Rationale: Piperazine-based designer drugs such as benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been marketed and sold as legal alternatives to dexamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) until 2008 in New Zealand. When administered in combination, BZP + TFMPP have been reported to produce drug-drug synergism in rodents by stimulating the release of dopamine and serotonin.

Objectives: This study was to evaluate the acute event-related potential effects of BZP, TFMPP or the combination of BZP + TFMPP compared with dexamphetamine in young healthy male adults.

Methods: A double-blind, randomised, placebo-controlled study investigated the effects of BZP, TFMPP, the combination of BZP + TFMPP, and dexamphetamine on the event-related potentials during an auditory oddball task. Healthy, right-handed males were given a single oral dose of either BZP (200 mg), TFMPP (60 mg), a combination of BZP + TFMPP (100/30 mg), dexamphetamine (20 mg) or placebo (lactose) and tested both before and 120 min after drug administration.

Results: A single dose of either TMFPP (t = -2.29, p = 0.03) or dexamphetamine (t = -2.33, p = 0.02) significantly reduced the P300 amplitude. A similar trend was also found in BZP. In contrast, BZP and TFMPP in combination has no effect. Neither P300 latency nor the mean reaction time was affected by any of the drug treatments. In addition, neither the P100 nor the P200 component was significantly affected following any of the drug treatments.

Conclusions: A single oral dose of BZP or TFMPP, but not the combination of BZP/TFMPP, affected auditory sensory-evoked P300 potential in a manner similar to dexamphetamine.

Citing Articles

An Update on the Implications of New Psychoactive Substances in Public Health.

Simao A, Antunes M, Cabral E, Oliveira P, Rosendo L, Brinca A Int J Environ Res Public Health. 2022; 19(8).

PMID: 35457736 PMC: 9028227. DOI: 10.3390/ijerph19084869.

Comparison of LC-MS and LC-DAD Methods of Detecting Abused Piperazine Designer Drugs.

Welz A, Koba M, Koslinski P, Siodmiak J J Clin Med. 2022; 11(7).

PMID: 35407366 PMC: 8999770. DOI: 10.3390/jcm11071758.

Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs.

Welz A, Koba M, Koslinski P, Siodmiak J J Clin Med. 2021; 10(24).

PMID: 34945109 PMC: 8704057. DOI: 10.3390/jcm10245813.

Involvement of the Serotonin Transporter Gene in Accurate Subcortical Speech Encoding.

Selinger L, Zarnowiec K, Via M, Clemente I, Escera C J Neurosci. 2016; 36(42):10782-10790.

PMID: 27798133 PMC: 6601888. DOI: 10.1523/JNEUROSCI.1595-16.2016.

Investigation of the effects of 'piperazine-containing party pills' and dexamphetamine on interhemispheric communication using electroencephalography.

Lee H, Wang G, Curley L, Kydd R, Kirk I, Russell B Psychopharmacology (Berl). 2016; 233(15-16):2869-77.

PMID: 27289365 DOI: 10.1007/s00213-016-4335-5.

References

Hansenne M, Pitchot W, Gonzalez Moreno A, Papart P, Timsit-Berthier M, Ansseau M . Catecholaminergic function and P300 amplitude in major depressive disorder (P300 and catecholamines). Electroencephalogr Clin Neurophysiol. 1995; 96(2):194-6. DOI: 10.1016/0168-5597(94)00317-8. View

Hausmann M, Hamm J, Waldie K, Kirk I . Sex hormonal modulation of interhemispheric transfer time. Neuropsychologia. 2013; 51(9):1734-41. DOI: 10.1016/j.neuropsychologia.2013.05.017. View

Nowicka A, Fersten E . Sex-related differences in interhemispheric transmission time in the human brain. Neuroreport. 2001; 12(18):4171-5. DOI: 10.1097/00001756-200112210-00061. View

Miele M, Mura M, Enrico P, Esposito G, Serra P, Migheli R . On the mechanism of d-amphetamine-induced changes in glutamate, ascorbic acid and uric acid release in the striatum of freely moving rats. Br J Pharmacol. 2000; 129(3):582-8. PMC: 1571853. DOI: 10.1038/sj.bjp.0703066. View

Hoyer D, Schoeffter P . 5-HT1D receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in calf substantia nigra. Eur J Pharmacol. 1988; 147(1):145-7. DOI: 10.1016/0014-2999(88)90645-0. View

Anokhin A, Vedeniapin A, Sirevaag E, Bauer L, OConnor S, Kuperman S . The P300 brain potential is reduced in smokers. Psychopharmacology (Berl). 2000; 149(4):409-13. DOI: 10.1007/s002130000387. View

Halliday R, NAYLOR H, Brandeis D, CALLAWAY E, Yano L, Herzig K . The effect of D-amphetamine, clonidine, and yohimbine on human information processing. Psychophysiology. 1994; 31(4):331-7. DOI: 10.1111/j.1469-8986.1994.tb02441.x. View

Lehmann D, Skrandies W . Reference-free identification of components of checkerboard-evoked multichannel potential fields. Electroencephalogr Clin Neurophysiol. 1980; 48(6):609-21. DOI: 10.1016/0013-4694(80)90419-8. View

Lazarev V . The relationship of theory and methodology in EEG studies of mental activity. Int J Psychophysiol. 2006; 62(3):384-93. DOI: 10.1016/j.ijpsycho.2006.01.006. View

10.

Alarcon G, Guy C, Binnie C . A simple algorithm for a digital three-pole Butterworth filter of arbitrary cut-off frequency: application to digital electroencephalography. J Neurosci Methods. 2001; 104(1):35-44. DOI: 10.1016/s0165-0270(00)00324-1. View

11.

Oranje B, Gispen-de Wied C, Westenberg H, Kemner C, Verbaten M, Kahn R . No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention. J Psychopharmacol. 2006; 20(6):789-98. DOI: 10.1177/0269881106061712. View

12.

Jan R, Lin J, Lee H, Sheridan J, Kydd R, Kirk I . Determining the subjective effects of TFMPP in human males. Psychopharmacology (Berl). 2010; 211(3):347-53. DOI: 10.1007/s00213-010-1911-y. View

13.

Polich J . Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol. 2007; 118(10):2128-48. PMC: 2715154. DOI: 10.1016/j.clinph.2007.04.019. View

14.

CALLAWAY E . Human information-processing: some effects of methylphenidate, age, and scopolamine. Biol Psychiatry. 1984; 19(5):649-62. View

15.

Fantegrossi W, Kiessel C, De La Garza 2nd R, Woods J . Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl). 2005; 181(3):529-36. DOI: 10.1007/s00213-005-0005-8. View

16.

Nishimura N, Ogura C, Ohta I . Effects of the dopamine-related drug bromocriptine on event-related potentials and its relation to the law of initial value. Psychiatry Clin Neurosci. 1995; 49(1):79-86. DOI: 10.1111/j.1440-1819.1995.tb01863.x. View

17.

Albrecht M, Martin-Iverson M, Price G, Lee J, Iyyalol R . Dexamphetamine-induced reduction of P3a and P3b in healthy participants. J Psychopharmacol. 2010; 25(12):1623-31. DOI: 10.1177/0269881110376686. View

18.

Jervis B, Nichols M, Allen E, Hudson N, Johnson T . The assessment of two methods for removing eye movement artefact from the EEG. Electroencephalogr Clin Neurophysiol. 1985; 61(5):444-52. DOI: 10.1016/0013-4694(85)91037-5. View

19.

Murray M, Brunet D, Michel C . Topographic ERP analyses: a step-by-step tutorial review. Brain Topogr. 2008; 20(4):249-64. DOI: 10.1007/s10548-008-0054-5. View

20.

Muller T, Kalus P, Strik W . The neurophysiological meaning of auditory P300 in subtypes of schizophrenia. World J Biol Psychiatry. 2003; 2(1):9-17. DOI: 10.3109/15622970109039979. View